




RFP-PD-2015-002

Intent to Apply (ITA)


A total of 17 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below: *



* One or more ITA forms included multiple diseases, interventions and/or development stages in the scope.

Full Proposal

A total of 11 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:*



* One or more proposals included multiple diseases, interventions and/or development stages in the scope.

Award Notification

The following five projects were awarded funding.

| Project Title | Collaboration Partners | Disease | Intervention | Development Stage | Total Amount |
|--|---|--------------------------------|--------------|-----------------------|--------------|
| Highly Sensitive POC TB-LAM Rapid Diagnostic Test | 1. Foundation for Innovative New Diagnostics (FIND) 2. Fujifilm Corporation | Tuberculosis | Diagnostics | Clinical | ¥216,057,769 |
| Cry5B consortium for soil-transmitted helminths | 1. PATH 2. Meiji Seika Pharma CO., LTD. 3. Ajinomoto Co., Inc. 4. University of Massachusetts, Amherst | Soil-transmitted helminthiasis | Drug | Pre-Clinical | ¥100,299,625 |
| Development of a fully automated malaria diagnostic system and field evaluation for practical use | 1. Panasonic corporation 2. Juntendo University 3. Kenya Medical Research Institute (KEMRI-CGHR) 4. National Institute of Advanced Industrial Science and Technology 5. Institute of Tropical Medicine, Nagasaki University 6. Malaria No More Japan | Malaria | Diagnostics | Pre-Clinical/Clinical | ¥96,450,000 |
| Preclinical efficacy of CpG D35 combination therapy for treatment of complicated cutaneous leishmaniasis | 1. Drugs for Neglected Diseases <i>initiative</i> (DNDi) 2. Gene Design, Inc. | Leishmaniasis | Drug | Pre-Clinical | ¥68,771,551 |
| Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both <i>P. falciparum</i> and <i>P. vivax</i> | 1. University of Florida 2. CellFree Sciences Co., Ltd. (CFS) | Malaria | Vaccine | Pre-Clinical | ¥41,928,575 |